Palo Alto, Calif. – December 10, 2013 – Cooley LLP announced today that it advised Xencor, Inc. on its initial public offering. Xencor, a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, now trades on the NASDAQ Global Market under the symbol "XNCR."
About Cooley LLP
Cooley's attorneys solve legal issues for entrepreneurs, investors and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and bet-the-company litigation, often where innovation meets the law.
Cooley has more than 700 lawyers across eleven offices in the United States and China.